Kaumann A J, Molenaar P
Babraham Institute, Human Pharmacology Laboratory, Cambridge, UK.
Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):667-81. doi: 10.1007/pl00004999.
In human heart there is now evidence for the involvement of four beta-adrenoceptor populations, three identical to the recombinant beta 1-, beta 2- and beta 3-adrenoceptors, and a fourth as yet uncloned putative beta-adrenoceptor population, which we designate provisionally as the cardiac putative beta 4-adrenoceptor. This review described novel features of beta-adrenoceptors as modulators of cardiac systolic and diastolic function. We also discuss evidence for modulation by unoccupied beta 1- and beta 2-adrenoceptors. Human cardiac and recombinant beta 1- and beta 2-adrenoceptors are both mainly coupled to adenylyl cyclase through Gs protein, the latter more tightly than the former. Activation of both human beta 1- and beta 2-adrenoceptors not only increases cardiac force during systole but also hastens relaxation through cyclic AMP-dependent phosphorylation of phospholamban and troponin 1, thereby facilitating diastolic function. Furthermore, both beta 1 and beta 2-adrenoceptors can mediate experimental arrhythmias in human cardiac preparations elicited by noradrenaline and adrenaline. Human ventricular beta 3-adrenoceptors appear to be coupled to a pertussis toxin-sensitive protein (Gi?). beta 3-Adrenoceptor-selective agonists shorten the action potential and cause cardiodepression, suggesting direct coupling of a Gi protein to a K+ channel. In a variety of species, including man, cardiac putative beta 4-adrenoceptors mediate cardiostimulant effects of non-conventional partial agonists, i.e. high affinity beta 1- and beta 2-adrenoceptor blockers that cause agonist effects at concentrations considerably higher than those that block these receptors. Putative beta 4-adrenoceptors appear to be coupled positively to a cyclic AMP-dependent cascade and can undergo some desensitisation.
目前有证据表明,人类心脏中有四种β-肾上腺素能受体亚型参与其中,其中三种与重组β1-、β2-和β3-肾上腺素能受体相同,第四种尚未克隆的假定β-肾上腺素能受体亚型,我们暂时将其命名为心脏假定β4-肾上腺素能受体。本综述描述了β-肾上腺素能受体作为心脏收缩和舒张功能调节剂的新特性。我们还讨论了未被占据的β1-和β2-肾上腺素能受体的调节证据。人类心脏和重组β1-和β2-肾上腺素能受体主要都通过Gs蛋白与腺苷酸环化酶偶联,后者比前者更紧密。人类β1-和β2-肾上腺素能受体的激活不仅增加收缩期心脏力量,还通过受磷蛋白和肌钙蛋白1的环磷酸腺苷依赖性磷酸化加速舒张,从而促进舒张功能。此外,β1和β2-肾上腺素能受体都可以介导去甲肾上腺素和肾上腺素引起的人类心脏制剂中的实验性心律失常。人类心室β3-肾上腺素能受体似乎与百日咳毒素敏感蛋白(Gi?)偶联。β3-肾上腺素能受体选择性激动剂缩短动作电位并导致心脏抑制,提示Gi蛋白直接与钾通道偶联。在包括人类在内的多种物种中,心脏假定β4-肾上腺素能受体介导非常规部分激动剂的心脏刺激作用,即高亲和力β1-和β2-肾上腺素能受体阻滞剂在浓度远高于阻断这些受体的浓度时产生激动剂作用。假定β4-肾上腺素能受体似乎正向偶联至环磷酸腺苷依赖性级联反应,并且可以发生一定程度的脱敏。